Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of Intravenous DWP14012 in Healthy Volunteers
NCT06508645Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fexuprazan in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to 24 hours, Percentage of time intragastric pH > 4 at 4 days and 1 more. Started Jan 2022; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06508645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508645.